Jan 10 (Reuters) - Shanghai Pharmaceuticals Holding Co Ltd
* Says Changzhou-based pharmaceuticals unit received goods manufacture practice (GMP) certificate from Jiangsu Food and Drug Administration, for its products including acyclovir, ganciclovir and production line
* Says the valid period is until Dec. 25, 2022
* Says Shanghai-based pharmaceuticals unit received goods manufacture practice (GMP) certificate from Shanghai Food and Drug Administration, for its products including flurbiprofen axetil
* Says the valid period is until Dec. 26, 2022
Source text in Chinese: goo.gl/15PQTv
Further company coverage: (Beijing Headline News)
Our Standards: The Thomson Reuters Trust Principles.